Navigation Links
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant prostate cancer (mCRPC). Data presented showed that ipilimumab monotherapy or in combination with radiotherapy was clinically active and generally well-tolerated. Preliminary evidence of anti-cancer activity showed that 21 percent of patients (7 of 33) experienced decreases in prostate-specific antigen (PSA) serum levels of over 50 percent, with median duration of PSA responses of 4.8 months. This included one patient treated at the highest dose with a complete response (measured by both PSA and RECIST criteria) ongoing over one year. Two additional patients had PSA reductions of more than 30 percent within 12 weeks of treatment. The interim results were described in an oral presentation by investigator Tomasz M. Beer, M.D., the Grover C. Bagby Endowed Chair for Prostate Cancer Research and Associate Professor of Medicine from Oregon Health & Science University Cancer Institute, at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago. (Abstract #5004)

"These initial data in patients with metastatic castration resistant prostate cancer demonstrated preliminary anti-tumor activity, including durable response, and is suggestive of a safety profile at the optimal ipilimumab regimen similar to that observed in our melanoma program," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Radiotherapy is routinely used for palliative treatment in patients with metastatic castrat
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
10. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... The Open Paradigm Project, in collaboration ... Psychiatry , and leading organizations in the movement ... media campaign showcasing video testimonials by individuals negatively ... on pathology and illness rather than wellness and ... Association,s (APA) rollout of its latest revision of ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, healthcare and to first responders ... its financial results for the fiscal 2013 fourth quarter ... 21, 2013 at stock market close and will conduct ... p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
(Date:5/17/2013)... 17, 2013   Shareholder rights attorneys  at Robbins ... Inc. (NASDAQGS: AVEO) securities has filed a complaint in ... Massachusetts .  The complaint alleges that Aveo ... Act of 1934 (the "Exchange Act") between January 3, ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
... N.C. , July 21 /PRNewswire-FirstCall / -- SPX ... completed the acquisition of the Anhydro business, a Soeborg, Denmark ... dewatering plants and equipment.  The terms of the transaction were not ... Anhydro ...
... DETROIT , July 21 Caraco Pharmaceutical ... shipping bupropion hydrochloride extended release tablets. This product was ... (FDA) for Sun Pharma,s Abbreviated New Drug Application (ANDA). ... mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline,s ...
Cached Medicine Technology:SPX Completes Acquisition of Anhydro 2SPX Completes Acquisition of Anhydro 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2
(Date:5/20/2013)... prepare for final exams, teens nationwide may be tempted ... or amphetamine -- to gain an academic edge. But ... in 100 parents of teens 13-17 years old believes ... drugs refer to stimulant medications typically prescribed for the ... medicines in this category include Adderall, Concerta, Ritalin, and ...
(Date:5/20/2013)... Join Seva Foundation in celebrating its 35th Anniversary ... of Fine Arts Theater in San Francisco, featuring: ... Shimshai, with host Wavy Gravy. All proceeds will benefit Seva ... Reserved seats are $40 & $55, VIP tickets are $150 ... front row seat at the show. Tickets are available through ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery ... the MedEx Pack announced. The new report ... in order to provide useful details for those who are ... Furuta, MedEx Direct owner and pharmacist said, “One of the ... product like the MedEx Pack, patients can receive their own ...
(Date:5/20/2013)... research from the University of Southampton has shown that ... use echolocation, similar to that used by bats and ... The study, which is published in the journal ... hearing of echoes, could help blind people with spatial ... effects of hearing impairment and how to optimise echolocation ...
(Date:5/20/2013)... WEDI, the leading authority on the use ... information, announced today at the WEDI 22nd Annual National ... Collaborative Initiative. The new initiative will bring together state ... efficiencies and reduce the significant time and costs associated ... initiative is to help facilitate inter-state communication around ICD-10 ...
Breaking Medicine News(10 mins):Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:WEDI Launches New ICD-10 State Collaborative Initiative to Increase Efficiencies and Reduce Compliance Time and Costs 2
... works, the greater his chances for high blood pressure, a new ... at the// University of California, Irvine analyzed more than 24,000 people ... found that people who worked 40 hours a week are 14 ... who work under 39 hours a week. Those who work 41 ...
... from Rensselaer Polytechnic Institute in Troy, N.Y., and the University ... the host receptors where anthrax toxin attaches in the body. ... bind to multiple sites on the host receptor making it ... site. The researchers found that the new approach led ...
... doctors were stranded for days at the Charity Hospital, when ... of the storm, Charles Gibson reports from that hospital. ... might think you're in a warehouse or some kind of ... ,Charity Hospital served the poor and uninsured people ...
... conjoined twins were separated after a lengthy surgery. 3 weeks ... to their father, it is an indication of their recovery., ... were conjoined at the trunk and shared several internal organs, ... various medical complications caused by the only kidney, the surgery ...
... draw a little closer in understanding the evolution of the ... be more infectious to people. ,According to ... influenza strains from the common human influenza. This conclusion follows ... type flu viruses. This analysis will also aid scientists trace ...
... the Northern Territory Government’s decision to fund rotavirus ... to follow suit and help// protect vulnerable children ... came after the Federal Government’s Pharmaceutical Benefits Advisory ... cost-effective to provide the rotavirus vaccine to all ...
Cached Medicine News:Health News:Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax 2Health News:Conjoined twins doing well after separation 2Health News:Understanding the Evolution of Viruses a little more Clearly 2
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: